{"url_path":"/sec/cers/10-k/2026/item-9b","section_key":"item-9b","section_title":"Item 9B Other Information","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-03-02","source_url":"https://www.sec.gov/Archives/edgar/data/1020214/0001193125-26-085678-index.html","accession_number":"0001193125-26-085678","cik":"0001020214","ticker":"CERS","issuer_name":"CERUS CORP","edgar_url":"https://www.sec.gov/Archives/edgar/data/1020214/0001193125-26-085678-index.html","primary_entity_key":"0001020214","primary_entity_name":"CERUS CORP"},"word_count":134,"has_tables":true,"body_markdown":"Item 9B. Other Information\n\nInsider Trading Arrangements\n\nOn November 14, 2025, Kevin Green, Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense conditions of rule 10b5-1(c) for the sale of up to 55,225 shares of the Company’s stock until March 20,2026.\n\nOn November 21, 2025, Richard Benjamin, Chief Medical Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense conditions of rule 10b5-1(c) for the sale of up to 262,869 shares of the Company’s stock until November 13,2026.\n\nOn December 15, 2025, Vivek Jayaraman, Chief Operating Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense conditions of rule 10b5-1(c) for the sale of up to 300,000 shares of the Company’s stock until March 16, 2027."}